Edwards' shares hit as US Sapien sales fall short of high expectations
This article was originally published in Clinica
Executive Summary
Edwards Lifesciences’ overall third-quarter results beat analyst forecasts, “driven by upside in surgical valves and international [transcatheter aortic valves],” noted Jefferies analyst Raj Denhoy.